Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 9/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | VNN1 | O95497 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6108973 | 0.90 | GFPT1 (0.73) | GFPT1GAAHPGDPDGFRBFLT4 | |
| SCHEMBL6107805 | 0.90 | GFPT1 (0.72) | GFPT1GAAHPGDPDGFRBFLT4 | |
| SCHEMBL6108977 | 0.88 | GFPT1 (0.70) | GFPT1GAAHPGDPDGFRBFLT4 | |
| SCHEMBL5745996 | 0.88 | GFPT1 (0.69) | GFPT1GAAHPGDPDGFRBFLT4 | |
| SCHEMBL5809762 | 0.87 | GFPT1 (1.00) | GFPT1GAAPDGFRBFLT4DGAT2 | |
| Trifluoroacetic Acid SCHEMBL6109077 | 0.87 | GFPT1 (0.68) | GFPT1GAAHPGDPDGFRBFLT4 | |
| Trifluoroacetic Acid SCHEMBL6111475 | 0.86 | GFPT1 (0.67) | GFPT1GAAHPGDDGAT2MEN1 | |
| SCHEMBL6108389 | 0.86 | GFPT1 (0.67) | GFPT1GAAHPGDPDGFRBFLT4 | |
| Trifluoroacetic Acid SCHEMBL6106759 | 0.85 | GFPT1 (0.81) | GFPT1PDGFRBFLT4PDE10AVNN1 | |
| SCHEMBL6109566 | 0.85 | GFPT1 (0.66) | GFPT1GAAHPGDDGAT2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | GFPT1 1/4885GAA 84/4885HPGD 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.